468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activati...
468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundToripalimab is a PD-1 targeting humanized IgG4 monoclonal antibody (mAb) that is currently pending approval by US Food and Drug Administration (FDA) for first-line treatment of nasopharyngeal carcinoma (NPC) in combination with chemotherapy. While currently approved PD-1 mAbs have demonstrated significant clinical benefit particularly in...
Alternative Titles
Full title
468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_be6e03e567ca486f9b68f511ad6c41df
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_be6e03e567ca486f9b68f511ad6c41df
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.0468
